tamoxifen citrate

January 2005
Taber's Cyclopedic Medical Dictionary;2005, p2141
Reference Entry
A definition of the term "tamoxifen citrate" is presented. It refers to an antiestrogenic drug used in treating and preventing breast cancer.


Related Articles

  • Déjà Vu for Breast Cancer Two? Stearns, Vered; Davidson, Nancy E. // JNCI: Journal of the National Cancer Institute;4/7/2004, Vol. 96 Issue 7, p497 

    Introduces the articles published in the April 2004 issue of the "Journal of the National Cancer Institute." Presentation of a combined retrospective analysis of the histology and estrogen receptor alpha and progesterone receptor status of the primary and subsequent colateral breast cancer in...

  • δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer. Shaocong Guo; Yaqing Li; Qi Tong; Feng Gu; Tianhui Zhu; Li Fu; Shuang Yang // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Resistance to tamoxifen therapy represents a major barrier to the successful treatment of breast cancer, where a loss of or reduced ER-α level is considered a primary mechanism. Understanding how ER-α expression is regulated would provide insights into new intervention points to overcome...

  • Meta-analysis of incidence of early lung toxicity in 3- dimensional conformal irradiation of breast carcinomas. Appalanaido, Gokula Kumar; Arul, Earnest; Wong Lea Choung // Radiation Oncology;2013, Vol. 8 Issue 1, p1 

    Background This meta-analysis aims to ascertain the significance of early lung toxicity with 3- Dimensional (3D) conformal irradiation for breast carcinomas and identify the sub-groups of patients with increased risk. Methods Electronic databases, reference sections of major oncological...

  • Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer. Kangaspeska, Sara; Hultsch, Susanne; Jaiswal, Alok; Edgren, Henrik; Mpindi, John-Patrick; Eldfors, Samuli; Brück, Oscar; Aittokallio, Tero; Kallioniemi, Olli // BMC Cancer;7/4/2016, Vol. 16, p1 

    Background: The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive cancers display de novo resistance to tamoxifen, and...

  • Delivering tamoxifen within solid lipid nanoparticles. Abbasalipourkabir, Roghayeh; Salehzadeh, Aref; Abdullah, Rasedee // Pharmaceutical Technology Europe;Apr2011, Vol. 23 Issue 4, p22 

    Solid lipid nanoparticles (SLNs) have been proposed as an alternative colloidal drug-delivery system for water-soluble drugs. The aim of this study was to prepare and characterise physiochemically and biologically tamoxifen-loaded SLNs to evaluate their effectiveness as a drug-delivery system to...

  • A new marker of tamoxifen resistance of estrogen receptor-positive breast cancer. Bogush, E. A.; Ravcheeva, A. B.; Bogush, T. A.; Zabotina, T. N.; Kadagidze, Z. G.; Davydov, M. I. // Doklady Biochemistry & Biophysics;Mar2007, Vol. 413 Issue 1, p83 

    The article discusses a new marker of tamoxifen resistance of estrogen receptor-positive breast cancer. According to the study, the main limitation in tamoxifen efficiency is hereditary and induced antiestrogen resistance, and one of possible factors underlying this phenomenon is alteration of...

  • Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain Cancer Free, Study Shows; Results From Pfizer-Sponsored Study Challenge Standard Tamoxifen Therapy.  // Ascribe Newswire: Medicine;3/22/2004, p22 

    Post-menopausal breast cancer patients who switched from tamoxifen to Aromasin had a significantly reduced chance of recurrence and increased disease-free survival compared to patients who remained on tamoxifen, according to new data published in the March 22, 2004 issue of the "New England...

  • Defining the Role of Raloxifene for the Prevention of Breast Cancer. Kalidas, Mamta; Hilsenbeck, Susan; Brown, Powel // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1731 

    Compares the ability of tamoxifen and raloxifene to reduce the incidence of breast cancer in postmenopausal women at high risk of breast cancer. Implication of the study on the decision of the clinicians whether to use tamoxifen or raloxifene for the prevention of breast cancer; Determination of...

  • Contralateral Breast Cancer and Thromboembolic Events in African American Women Treated With Tamoxifen. McCaskill-Stevens, Worta; Wilson, John; Bryant, John; Mamounas, Eleftherios; Garvey, Lori; James, Joan; Cronin, Walter; Wickerham, D. Lawrence // JNCI: Journal of the National Cancer Institute;12/1/2004, Vol. 96 Issue 23, p1762 

    Background: Information about breast cancer treatment and prevention in African American women is scant, and recommendations for therapy from clinical trials for breast cancer are based primarily on data obtained from white women. Methods: We compared the effects of tamoxifen on risk of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics